Your browser doesn't support javascript.
loading
Percutaneous biliary drainage for obstructive jaundice in patients with inoperable, malignant biliary obstruction.
Zerem, Enver; Imsirovic, Bilal; Kunosic, Suad; Zerem, Dina; Zerem, Omar.
Afiliación
  • Zerem E; Academy of Sciences and Arts of Bosnia and Herzegovina, Bosnia and Herzegovina.
  • Imsirovic B; Department of Radiology, General Hospital "Prim. Dr. Abdulah Nakas", Sarajevo, Bosnia and Herzegovina, Bosnia and Herzegovina.
  • Kunosic S; Department of Physics, Faculty of Natural Sciences and Mathematics, University of Tuzla, Tuzla, Bosnia and Herzegovina.
  • Zerem D; Department of Internal Medicine, Cantonal Hospital "Safet Mujic", University of Mostar, Mostar, Bosnia and Herzegovina.
  • Zerem O; Department of Internal Medicine, Cantonal Hospital "Safet Mujic", University of Mostar, Mostar, Bosnia and Herzegovina.
Clin Exp Hepatol ; 8(1): 70-77, 2022 Mar.
Article en En | MEDLINE | ID: mdl-35415254
ABSTRACT
Aim of the study Most of the malignancies leading to obstructive jaundice are diagnosed too late when they are already advanced and inoperable, with palliation being the only treatment option left. Due to progressing hyperbilirubinaemia with its consequent adverse effects, biliary drainage must be established even in advanced malignancies. This study aims to investigate and analyse factors that affect clinical outcomes of percutaneous trans-hepatic biliary drainage (PTBD) in patients with obstructive jaundice due to advanced inoperable malignancy, and identify potential predictors of patient survival. Study

design:

Observational retrospective cohort study. Material and

methods:

Baseline variables and clinical outcomes were evaluated in 108 consecutive patients treated with PTBD. The study's primary endpoints were significant bilirubin level decrease and survival rates. Secondary endpoints included periprocedural major and minor complication rates and catheter primary and secondary patency rates.

Results:

PTBD was technically successful and bile ducts were successfully drained in all 108 patients. Median serum bilirubin level, which was 282 (171-376) µmol/l before drainage, decreased significantly, to 80 (56-144) µmol/l, 15 days after stent placement (p < 0.001). Patient survival ranged from 3 to 597 days and the overall (median) survival time following PTBD was 168 days (90-302). The 1, 3, 6, 12 and 18-month survival rates were 96.3%, 75.9%, 48.1%, 8.3% and 1.9%, respectively. Multivariate analysis revealed that liver metastases and alkaline phosphatase were significantly associated with mortality. The overall complication rate was 9.3%.

Conclusions:

PTBD is a safe and effective method to relieve jaundice caused by advanced inoperable malignant disease. Careful patient selection is necessary when introducing PTBD in order to avoid invasive procedures in patients with a poor prognosis.
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Clin Exp Hepatol Año: 2022 Tipo del documento: Article

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Clin Exp Hepatol Año: 2022 Tipo del documento: Article